<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362601">
  <stage>Registered</stage>
  <submitdate>6/06/2012</submitdate>
  <approvaldate>27/06/2012</approvaldate>
  <actrnumber>ACTRN12612000691842</actrnumber>
  <trial_identification>
    <studytitle>Dynamic changes in clot formation using Thromboelastometry after reinfusion of unwashed cell salvaged whole blood in total hip arthroplasty: a pilot study</studytitle>
    <scientifictitle>Dynamic changes in clot formation using Thromboelastometry after reinfusion of unwashed cell salvaged whole blood in total hip arthroplasty</scientifictitle>
    <utrn />
    <trialacronym>nil</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>shed blood</healthcondition>
    <healthcondition>reinfusion</healthcondition>
    <healthcondition>clot formation</healthcondition>
    <healthcondition>coagulopathy</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>to evaluate if the reinfusion of cellsalvaged whole blood will impact on coagulation observed in standard laboratory testing and/or thrombelasometry. A minimum of 300ml blood is collected during hip replacement surgery using the SANGVIA cell saver system, filtered and then reinfused immediately post-operatively</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>standard coagulation test (INR/aPPT) and assessed using point of care device, "ROTEM".thrombelastometry in addition to cytokine analysis of the collected blood</outcome>
      <timepoint>outcome assessed at one time point within 1 hour of postoperative  reinfusion of intraoperative cellsalvaged blood</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>haemoglobin post op</outcome>
      <timepoint>post op day one or two</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>haemoglobin at discharge</outcome>
      <timepoint>Hb closest to discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>allogeneic transfusion of red blood cells</outcome>
      <timepoint>this hospital stay</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>cytokines in salvaged blood before reinfusion</outcome>
      <timepoint>analysed post completion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>primary hip replacement</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>contraindication to reinfusion of shed blood, pateint refusal,
pre-existing coagulopathy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>consented patients for primary hip arthroplasty</concealment>
    <sequence>NA</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>8/06/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Astra Tech AB</primarysponsorname>
    <primarysponsoraddress>PO Box 14
SE-431 21</primarysponsoraddress>
    <primarysponsorcountry>Sweden</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Astra Tech AB</fundingname>
      <fundingaddress>PO Box 14
SE-431 21</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>BloodSafe</fundingname>
      <fundingaddress>301 Pirie Street
 Adelaide 
South Australia 
5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>HaemoVIEW Diagnostics Pty Ltd</fundingname>
      <fundingaddress>HaemoVIEW Diagnostics Pty Ltd
73 Osna Place
Pullenvale
Brisbane 4069
Queensland</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>HaemoVIEW Diagnostics Pty Ltd</sponsorname>
      <sponsoraddress>HaemoVIEW Diagnostics Pty Ltd
73 Osna Place
Pullenvale
Brisbane 4069
Queensland</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>BloodSafe</sponsorname>
      <sponsoraddress>301 Pirie Street
 Adelaide 
South Australia 
5000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A pilot study:
As part of our standard care, in line with a comprehensive blood management approach, patients presenting for primary hip arthroplasty are offered intra-operative cell salvage. One type of cell saver used is the SANGVIA system. Blood is collected during surgery, filtered and  can be reinfused post-operatively. This is a relatively new technology and there is some controversy around the efficacy, safety and potential adverse effects of the reinfusion. This includes  some concern whether a coagulopathy might be induced by reinfusion through various mechamisms.  of cytokines.
A "point of care device" "ROTEM" is well established in clinical medicine. It is comprehensive diagnostic system coagulation management.
We would like to assess the patients' clotting profile before incision  and the potential impact of  reinfusion of the salvaged blood at the end of the operation. This will be conducted with ROTEM , testing for ex-TEM S (screening extrinsic clotting pathway &amp; platelet contribution to clot formation), in-TEM S (screening intrinsic clotting pathway &amp; platelet contribution to clot formation)compared to standard Lab testing (INR, aPTT).
 A small sample volume of the shed blood is collected and analyed for haemoglobin and platelets to assess the quality and composition of the blood. In addition a 2nd sample is frozen which will be analyzed after completion of the study to assess the presence and levels of imflammatory mediators.</summary>
    <trialwebsite>nil</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ETHICS OF HUMAN RESEARCH COMMITTEE (TQEH &amp; LMH)</ethicname>
      <ethicaddress>Executive Officer, Human Research Ethics Committee

The Queen Elizabeth Hospital, Lyell McEwin Hospital &amp; Modbury Hospital
Adelaide Health Service

Ground Floor, Basil Hetzel Institute for Medical Research, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South SA 5011</ethicaddress>
      <ethicapprovaldate>3/06/2011</ethicapprovaldate>
      <hrec>NA</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Bernd Froessler</name>
      <address>Dept of Anaesthesia
Lyell McEwin Hospital
Haydown Rd
Elizabeth Vale SA 5112</address>
      <phone>+61881829806</phone>
      <fax />
      <email>bernd.froessler@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Bernd Froessler</name>
      <address>Dept of Anaesthesia
Lyell McEwin Hospital
Haydown Rd
Elizabeth Vale SA 5112</address>
      <phone>+61881829806</phone>
      <fax />
      <email>bernd.froessler@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Bernd Froessler</name>
      <address>Dept of Anaesthesia
Lyell McEwin Hospital
Haydown Rd
Elizabeth Vale SA 5112</address>
      <phone>+61881829806</phone>
      <fax />
      <email>bernd.froessler@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>